Organon Fourth Quarter and Full Year 2025 Earnings Disclaimer statement Cautionary Note Regarding Non-GAAP Financial Measures This presentation contains "non-GAAP financial measures," which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Specifically, the company makes use of the non-GAAP financial measure ...

Financial Performance - Revenue for Q3 2025 was $1602 million, a 1% increase compared to Q3 2024[13] - Adjusted EBITDA for Q3 2025 was $518 million, with a 323% Adjusted EBITDA margin[13] - Adjusted diluted EPS for Q3 2025 was $101, compared to $087 in Q3 2024, a 16% increase[13] - The full-year revenue range is revised to $6200 million - $6250 million, with an Adjusted EBITDA margin guidance revised to approximately 310%[13] - Free Cash Flow before one-time costs YTD September 2025 was $813 million, compared to $693 million in 2024[32] Revenue Analysis by Segment - Total Women's Health revenue was $429 million in Q3 2025, a decrease of 3% compared to Q3 2024[17] However, year-to-date Women's Health revenue increased by 3% to $1354 million[15,17] - Nexplanon revenue was $223 million in Q3 2025, a decrease of 8% compared to Q3 2024[17] - Total Biosimilars revenue was $196 million in Q3 2025, a 19% increase compared to Q3 2024[20] Year-to-date Biosimilars revenue increased by 2% to $510 million[20] - Hadlima revenue increased by 57% to $63 million in Q3 2025[20] - Total Established Brands revenue was $956 million in Q3 2025, a 1% increase compared to Q3 2024[24] Year-to-date Established Brands revenue decreased by 5% to $2778 million[24] Geographic Performance - United States revenue increased by 2% to $406 million in Q3 2025[56] - Europe and Canada revenue decreased by 4% to $417 million in Q3 2025[56] - Latin America, Middle East, Russia and Africa revenue increased by 18% to $286 million in Q3 2025[56] Guidance - Full-year revenue guidance is revised to $6200 million - $6250 million, representing a nominal revenue growth of (32%) - (24%)[39] - Adjusted EBITDA margin guidance is revised to approximately 310%[39]

Financial Performance - Revenue for Q1 2025 was $1.513 billion, a decrease of 7% as reported and 4% ex-FX, compared to $1.622 billion in Q1 2024[13, 53] - Adjusted EBITDA was $484 million, representing a 32% Adjusted EBITDA margin[13] - Adjusted diluted EPS was $1.02[13] - Free Cash Flow was $71 million, improved from $6 million in Q1 2024[30] Segment Performance - Women's Health franchise grew by 12% ex-FX, with total revenue of $463 million[17, 20] - Nexplanon is on track to achieve over $1 billion in revenue in 2025[20] - Biosimilars revenue was $141 million, a decrease of 15% ex-FX[21] - Established Brands revenue was $887 million, a decrease of 8% ex-FX[25] Geographic Performance - The U S represents approximately 27% of total Organon revenue[15] - Approximately 75% of FY sales are generated ex-US[15] Guidance and Outlook - Full year 2025 revenue guidance is unchanged at $6 125 billion-$6 325 billion[42] - The company anticipates a foreign exchange translation headwind of approximately $200 million, but there is potential upside at current rates[42]